Skip to main content
. Author manuscript; available in PMC: 2017 May 17.
Published in final edited form as: ACS Macro Lett. 2015 Sep 11;4(10):1081–1084. doi: 10.1021/acsmacrolett.5b00545

Figure 2.

Figure 2

Effect of M-Dox and electroporation treatment on Hep3B viability. (A) Hep3B viability after electroporation at different field strength. (B) Hep3B viability after treatment with M-Dox, reversible electroporation (RE, 500 V/cm), and combination of RE + M-Dox. The combination group had the lowest cell viability among all four groups (p < 0.05).